세계의 레드 바이오테크놀러지 시장 규모 조사 및 예측 : 제품별, 최종 사용자별 및 지역별 분석(2023-2030년)

Global Red Biotechnology Market is valued at approximately USD 515.58 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 10.6% over the forecast period 2023-2030., Red biotechnology, also known as medical biotechnology, refers to the branch of biotechnology that focuses on using living organisms or their products to develop new medical and pharmaceutical products and applications. This field is called "red" biotechnology because it primarily deals with healthcare-related applications, and the color red is often associated with the medical and pharmaceutical industries. The key factors driving the market growth is Increasing Healthcare Expenditure, growing old age population, Rising Prevalence of Chronic Diseases, and growing development and production of biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and vaccines that anticipated to support the market growth during projected period.

According to The World Bank, in 2020, it was expected that aging people around the world accounted for 1 billion, which is projected to reach 1.5 billion by the year 2030 which represents that 1 in 6 people are more than 60 years of age. As a result, the growing old age population is anticipated to support the market growth. Additionally, growing research and development activities is anticipated to create the lucrative opportunity for the market during forecast period.

However, the costly therapeutic technology and machinery stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Red Biotechnology Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the presence of key market players, rising healthcare expenditure, and growing research and development activities. Whereas, the Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the growing old age population, rising demand for the personalized medicine, and growing Clinical Trials and Research that anticipated to support the region growth.

Major market player included in this report are:

• F. Hoffmann-La Roche AG
• Pfizer Inc
• Regeneron Pharmaceuticals, Inc
• Gilead Sciences Inc.
• Biogen Inc.
• Amgen Inc.
• Celgene Corporation
• Takeda Pharmaceutical Company Limited
• AstraZeneca Plc
• Merck KGaA

Recent Developments in the Market:

• In August 2022, The U.S. FDA approved MYFEMBREE, a once-daily medication produced by Myovant Sciences and Pfizer with a 24-month maximum treatment period, for the management of moderate to severe endometriosis-related pain. For the management of mild to severe endometriosis-related pain, MYFEMBREE offers an effective once-daily therapeutic alternative.

Global Red Biotechnology Market Report Scope:

• Historical Data - 2020 - 2021
• Base Year for Estimation - 2022
• Forecast period - 2023-2030
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered - Product, End-User, Region
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:

• Monoclonal Antibodies
• Polyclonal Antibodies
• Recombinant Proteins
• Vaccines
• Cell-Based Immunotherapy Products
• Gene Therapy Products
• Cell Therapy Products
• Tissue-Engineered Products
• Stem Cells
• Cell Culture
• Viral Vector
• Enzymes
• Kits and Reagents
• Animal models
• Molecular diagnostics
• Others

By End-User:

• Academic Research Institutes
• CMOs & CROs
• Pharmaceutical & Biotechnology Companies
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Red Biotechnology Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2. Red Biotechnology Market, by Product, 2020-2030 (USD Billion)
  • 1.2.3. Red Biotechnology Market, by End-user, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Red Biotechnology Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Red Biotechnology Market Dynamics

• 3.1. Red Biotechnology Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Increasing prevalence of chronic diseases
    • 3.1.1.2. Advances in genomics and personalized medicine
    • 3.1.1.3. Aging population and increased healthcare expenditure
  • 3.1.2. Market Challenges
    • 3.1.2.1. Intellectual Property and Patent Issues
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Growing Research and Development

Chapter 4. Global Red Biotechnology Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Red Biotechnology Market, by Product

• 5.1. Market Snapshot
• 5.2. Global Red Biotechnology Market by Product , Performance - Potential Analysis
• 5.3. Global Red Biotechnology Market Estimates & Forecasts by Product 2020-2030 (USD Billion)
• 5.4. Red Biotechnology Market, Sub Segment Analysis
  • 5.4.1. Monoclonal Antibodies
  • 5.4.2. Polyclonal Antibodies
  • 5.4.3. Vaccines
  • 5.4.4. Cell-Based Immunotherapy Products
  • 5.4.5. Gene Therapy Products
  • 5.4.6. Cell Therapy Products
  • 5.4.7. Tissue-Engineered Products
  • 5.4.8. Stem Cells
  • 5.4.9. Cell Culture
  • 5.4.10. Viral Vector
  • 5.4.11. Enzymes
  • 5.4.12. Kits and Reagents
  • 5.4.13. Animal models
  • 5.4.14. Molecular diagnostics
  • 5.4.15. Others

Chapter 6. Global Red Biotechnology Market, by end-user

• 6.1. Market Snapshot
• 6.2. Global Red Biotechnology Market by end-use, Performance - Potential Analysis
• 6.3. Global Red Biotechnology Market Estimates & Forecasts by end-user 2020-2030 (USD Billion)
• 6.4. Red Biotechnology Market, Sub Segment Analysis

6.4.1. Academic Research Institutes

6.4.2. CMOs & CROs

6.4.3. Pharmaceutical & Biotechnology Companies

6.4.4. Others

Chapter 7. Global Red Biotechnology Market, Regional Analysis

• 7.1. Top Leading Countries
• 7.2. Top Emerging Countries
• 7.3. Red Biotechnology Market, Regional Market Snapshot
• 7.4. North America Red Biotechnology Market
  • 7.4.1. U.S. Red Biotechnology Market
    • 7.4.1.1. Product breakdown estimates & forecasts, 2020-2030
    • 7.4.1.2. end-user breakdown estimates & forecasts, 2020-2030
  • 7.4.2. Canada Red Biotechnology Market
• 7.5. Europe Red Biotechnology Market Snapshot
  • 7.5.1. U.K. Red Biotechnology Market
  • 7.5.2. Germany Red Biotechnology Market
  • 7.5.3. France Red Biotechnology Market
  • 7.5.4. Spain Red Biotechnology Market
  • 7.5.5. Italy Red Biotechnology Market
  • 7.5.6. Rest of Europe Red Biotechnology Market
• 7.6. Asia-Pacific Red Biotechnology Market Snapshot
  • 7.6.1. China Red Biotechnology Market
  • 7.6.2. India Red Biotechnology Market
  • 7.6.3. Japan Red Biotechnology Market
  • 7.6.4. Australia Red Biotechnology Market
  • 7.6.5. South Korea Red Biotechnology Market
  • 7.6.6. Rest of Asia Pacific Red Biotechnology Market
• 7.7. Latin America Red Biotechnology Market Snapshot
  • 7.7.1. Brazil Red Biotechnology Market
  • 7.7.2. Mexico Red Biotechnology Market
• 7.8. Middle East & Africa Red Biotechnology Market
  • 7.8.1. Saudi Arabia Red Biotechnology Market
  • 7.8.2. South Africa Red Biotechnology Market
  • 7.8.3. Rest of Middle East & Africa Red Biotechnology Market

Chapter 8. Competitive Intelligence

• 8.1. Key Company SWOT Analysis
  • 8.1.1. Company 1
  • 8.1.2. Company 2
  • 8.1.3. Company 3
• 8.2. Top Market Strategies
• 8.3. Company Profiles
  • 8.3.1. F. Hoffmann-La Roche AG
    • 8.3.1.1. Key Information
    • 8.3.1.2. Overview
    • 8.3.1.3. Financial (Subject to Data Availability)
    • 8.3.1.4. Product Summary
    • 8.3.1.5. Recent Developments
  • 8.3.2. Pfizer Inc
  • 8.3.3. Regeneron Pharmaceuticals, Inc
  • 8.3.4. Gilead Sciences Inc.
  • 8.3.5. Biogen Inc.
  • 8.3.6. Amgen Inc.
  • 8.3.7. Celgene Corporation
  • 8.3.8. Takeda Pharmaceutical Company Limited
  • 8.3.9. AstraZeneca Plc
  • 8.3.10. Merck KGaA

Chapter 9. Research Process

• 9.1. Research Process
  • 9.1.1. Data Mining
  • 9.1.2. Analysis
  • 9.1.3. Market Estimation
  • 9.1.4. Validation
  • 9.1.5. Publishing
• 9.2. Research Attributes
• 9.3. Research Assumption